

Chromosome instability induced by *Mps1* and *p53* mutation generates aggressive lymphomas exhibiting aneuploidy-induced stress

Floris Foijer^{a,b,c,1,2}, Stephanie Z. Xie^{b,1,3}, Judith E. Simon^a, Petra L. Bakker^a, Nathalie Conte^c, Stephanie H. Davis^b, Eva Kregel^d, Jos Jonkers^d, Allan Bradley^c, and Peter K. Sorger^{b,2}

^aEuropean Research Institute for the Biology of Ageing, University of Groningen, University Medical Center Groningen, NL-9713 AV, Groningen, The Netherlands; ^bDepartment of Systems Biology, Harvard Medical School, Boston, MA 02115; ^cMouse Genomics, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, United Kingdom; and ^dDivision of Molecular Pathology, The Netherlands Cancer Institute, NL-1066 CX, Amsterdam, The Netherlands

Edited by Don W. Cleveland, University of California, San Diego, La Jolla, CA, and approved August 5, 2014 (received for review January 17, 2014)

Aneuploidy is a hallmark of human solid cancers that arises from errors in mitosis and results in gain and loss of oncogenes and tumor suppressors. Aneuploidy poses a growth disadvantage for cells grown in vitro, suggesting that cancer cells adapt to this burden. To understand better the consequences of aneuploidy in a rapidly proliferating adult tissue, we engineered a mouse in which chromosome instability was selectively induced in T cells. A flanked by *Lox* mutation was introduced into the monopolar spindle 1 (*Mps1*) spindle-assembly checkpoint gene so that Cre-mediated recombination would create a truncated protein (*Mps1*^{DK}) that retained the kinase domain but lacked the kinetochore-binding domain and thereby weakened the checkpoint. In a sensitized *p53*^{+/-} background we observed that *Mps1*^{DK/DK} mice suffered from rapid-onset acute lymphoblastic lymphoma. The tumors were highly aneuploid and exhibited a metabolic burden similar to that previously characterized in aneuploid yeast and cultured cells. The tumors nonetheless grew rapidly and were lethal within 3–4 mo after birth.

chromosomal instability | mouse models | CIN | tumor metabolism | T-cell acute lymphoblastic lymphoma

Aneuploidy is a hallmark of oncogenesis, affecting two out of three cancers (1). Aneuploidy arises during mitosis as a result of chromosomal instability (CIN) (2–4). The frequent occurrence of CIN in solid human tumors suggests a fundamental link between aneuploidy and cancer (5). However, primary mouse embryonic fibroblasts (MEFs) carrying a supernumerary chromosome have decreased proliferative potential, as do cells isolated from Down syndrome patients (6, 7) implying that chromosome imbalance imposes a physiological burden that lowers fitness, at least in untransformed cells (6, 8–10). In some mouse models, CIN appears to have a significant impact on lifespan at the organismal level, with increased aneuploidy decreasing life expectancy and vice versa (11–13). However, how the fitness cost imposed by CIN is balanced by its potential to promote oncogenic transformation remains poorly understood.

Mouse models of CIN involving conditional or hypomorphic mutations in spindle-assembly checkpoint (SAC) genes provide a means to study aneuploidy and assess its impact on cell fitness and oncogenesis. The SAC detects the presence of maloriented or detached kinetochores during mitosis and arrests cells in metaphase until all pairs of sister chromatids achieve the bioriented geometry that is uniquely compatible with normal disjunction (14–16). The SAC constitutes a signaling cascade [comprising monopolar spindle 1 (*Mps1*), Bub, Mad, CenpE, and RZZ proteins] that blocks activation of the anaphase-promoting complex, and thus mitotic progression, until all chromosomes are properly aligned (17). In the mouse, germ-line deletion of SAC genes results in early embryonic lethality, whereas heterozygous knockout of *Mad2* and other SAC genes generates relatively weak tumor phenotypes late in life (2–4). Paradoxically, some SAC mutations (e.g., *CenpE* heterozygosity) appear to be both tumor

predisposing and tumor suppressing, depending on the context (18). Hypomorphic *BubR1* mutations also have the unexpected property of promoting progeria (11).

Conditional mutations typically yield tumor phenotypes more representative of human disease than germ-line mutations (19), but conditional alleles have been little studied in the case of the spindle checkpoint. We therefore engineered a conditional flanked by *Lox* (FLOX) mutation into *Mps1*, a gene thought to function upstream in the SAC pathway (20) and then selectively truncated the protein by expressing Cre recombinase in T cells. The *Mps1* truncation (deletion in the kinetochore domain; *Mps1*^{DK}) removes the kinase-targeting domain but leaves the rest of the protein intact. We show that expression of this truncated protein causes chromosomal instability in MEFs and aneuploidy in two different Cre-expressing mouse lines. *Mps1* truncation in combination with heterozygous *p53* deletion leads to early-onset lymphoblastic lymphoma and consequent death. In lymphoma cells, changes in the expression of metabolic, splicing, and DNA-synthesis

Significance

Normal cells rarely missegregate chromosomes, but the majority of cancer cells have a chromosomal instability (CIN) phenotype that makes errors more common and results in abnormal chromosomal content (aneuploidy). Although aneuploidy promotes transformation via gain of oncogenes and loss of tumor suppressors, it also slows cell proliferation and disrupts metabolic homeostasis. Aneuploidy therefore represents a liability as well as a source of selective advantage for cancer cells. We provoked CIN in murine T cells by weakening the spindle-assembly checkpoint and then studied the consequences. We found that CIN dramatically accelerates cancer in a genetically predisposed background and that the resulting aneuploid cancers are metabolically deranged, a vulnerability that may open new avenues to treating aneuploid cancers.

Author contributions: F.F., S.Z.X., and P.K.S. designed research; F.F., S.Z.X., J.E.S., P.L.B., S.H.D., and E.K. performed research; N.C. and A.B. contributed new reagents/analytic tools; F.F., S.Z.X., J.E.S., N.C., J.J., A.B., and P.K.S. analyzed data; and F.F. and P.K.S. wrote the paper.

The authors declare no conflict of interest.

This article is a PNAS Direct Submission.

Freely available online through the PNAS open access option.

Data deposition: The data reported in this paper have been deposited in the Gene Expression Omnibus (GEO) database, www.ncbi.nlm.nih.gov/geo (accession no. GSE57334).

¹F.F. and S.Z.X. contributed equally to this work.

²To whom correspondence may be addressed. Email: f.foijer@umcg.nl or peter_sorger@hms.harvard.edu.

³Present address: Princess Margaret and Toronto General Hospitals, University Health Network, Toronto, Canada M5G 2C1.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1400892111/-DCSupplemental.

genes are very similar to changes previously identified in aneuploid yeast and cultured murine cells (6, 8) and appear to constitute a hallmark of chromosomal imbalance.

Results

To provoke CIN in a tissue-restricted fashion, we engineered a conditional *Mps1^f* truncation allele by flanking exons 3 and 4 of the *Mps1* locus with lox-sites; correct targeting of *Mps1* in mouse ES cells was confirmed by Southern blotting and RT-PCR (Fig. S1 A–C and SI Materials and Methods). Upon expression of Cre recombinase (21), the *Mps1^f* allele generates a truncated *Mps1* kinase lacking residues 47–154, a domain involved in kinetochore binding (Fig. 1A) (22). When expressed in MEFs as a GFP fusion, the *Mps1^{DK}* protein had the anticipated molecular weight but, unlike wild-type *Mps1*-GFP, did not accumulate to the same levels on prometaphase kinetochores [Fig. 1B (compare upper and lower




Fig. 1. *Mps1* truncation leads to mitotic delay, severe abnormalities, and a weakened SAC. (A) Schematic representation of the *Mps1* truncation allele. (B) Time-lapse image stills showing clear kinetochore localization of retrovirally transduced wild-type GFP-*Mps1* in prometaphase (Upper) and reduced binding of GFP-*Mps1^{DK}* to kinetochores (Lower) in MEFs. DNA was labeled with retroviral H2B-Cherry. (C) PCR detecting the truncation/deletion alleles for *Mps1* in genomic DNA isolated from control or Cre-infected *Mps1^{f/f}* MEFs. (D) Average mitotic index of Dox-inducible, Cre-transduced MEFs after 6 h of nocodazole treatment. The mitotic index is the percentage of mitotic cells as measured by phospho-histone H3 (pH3) staining. Error bars show the SEM of at least four biological replicates. (E) Average time of mitotic exit for nocodazole-arrested control *Mps1^{f/f}* (blue) or Cre-infected *Mps1^{f/f}* (red) MEFs. (F) Average duration of mitosis (Upper) and time from metaphase to cytokinesis (Lower) of *Mps1^{f/f}* control (blue) and Cre-infected (red) MEFs as determined by time-lapse microscopy. Error bars show the SEM of the number of cells indicated within the bar. (G) Distribution of mitotic phenotypes for control and Cre-infected *Mps1^{f/f}* MEFs as observed by time-lapse microscopy. Tetraploidization: a seemingly normal cell failed cytokinesis, resulting in one large tetraploid cell; binucleation: a seemingly normal cell failed cytokinesis, resulting in one cell with two nuclei; polyploidization: a seemingly tetraploid or polyploid cell failed cytokinesis, resulting in a polyploid cell; failed mitosis: a combination of mitotic errors.

panels), Fig. S1 D and E, and Movies S1 and S2]. We conclude that the *Mps1^{DK}* mutation impairs but does not prevent kinetochore binding, a conclusion supported by overexpression studies in human MCF 10A cells (Fig. S1 F and G and Movies S3 and S4).

The *Mps1^{DK}* Truncation Weakens the SAC and Causes CIN. To determine the consequences of *Mps1* mutation for chromosome segregation at a cellular level, we isolated *Mps1^{f/f}* embryos, generated MEFs, and transduced them with retroviruses expressing doxycycline (Dox)-inducible Cre (GFP-T2A-Cre). We found that exposure of these cells to Dox resulted in highly efficient switching, yielding *Mps1^{DK}* MEFs within 24–48 h (Fig. 1C, compare lanes 1 and 2 with lane 4). Some recombination also was observed in the absence of Dox (Fig. 1C, lane 3). When treated with the spindle poison nocodazole, both control *Mps1^{f/f}* and *Mps1^{DK}* MEFs arrested in mitosis, showing that both cell types can respond to spindle disassembly (Fig. 1D). However, when time-lapse imaging was used to assay the duration of arrest, *Mps1^{DK/DK}* cells were observed to exit mitosis 150 ± 16 min after DNA condensation, in contrast to 264 ± 15 min in control cells (congenic *Mps1^{f/f}* cells not exposed to Cre), a significant difference ($P < 0.0001$) (Fig. 1E). The observation that cells expressing *Mps1^{DK}* are unable to sustain mitotic arrest in the presence of spindle damage suggests that the SAC is impaired but not inactivated by the *Mps1^{DK}* mutation (23) and confirms our goal in creating the allele.

Time-lapse imaging in the absence of nocodazole showed that H2B-Cherry-transduced *Mps1^{DK}* MEFs spent $\sim 40\%$ longer in mitosis than control cells (Fig. 1F and Fig. S1H). In addition, they frequently contained lagging chromosomes (Fig. 1F and G and Movies S5, S6, and S7; control cells are shown in Movies S8 and S9), and half of all the cells failed to form a proper metaphase plate (Movie 10), resulting in polyploidy (Fig. 1G and Movie S11). Although this extended mitosis might appear to be a paradoxical phenotype for a SAC hypomorph, it has been shown that other SAC proteins both promote and sense chromosome-microtubule attachment and that partial inactivation of these proteins actually lengthens mitosis because the residual SAC function is able to sense incomplete attachment (22). We conclude that the *Mps1^{DK}* mutation causes a partial loss of checkpoint function and also impairs kinetochore-microtubule attachment, preventing *Mps1^{DK}* cells from stably arresting in the presence of spindle poisons and missegregating chromosomes under normal growth conditions (22).

***Mps1^{DK}* Provokes Aggressive T-Cell Acute Lymphoblastic Lymphoma in a p53 Heterozygous Background.** The *Mps1^{DK}* truncation was introduced into a highly mitotic, nonessential adult tissue by crossing *Mps1^{f/f}* mice with animals bearing a T-cell-specific *Lck-Cre* transgene (24). PCR revealed efficient switching of *Mps1^f* to *Mps1^{DK}* in T cells from 8- to 10-wk-old animals (Fig. S24) concomitant with changes in the DNA content of G1 thymocytes (compare peak width and coefficient of variation for G1 peaks in *Mps1^{DK}* and wild-type animals in Fig. 2A and B), but life span was unaffected (Fig. 2C, red line). When *Mps1^{f/f}* *Lck-Cre⁺* and wild-type control mice were injected with paclitaxel, a microtubule-stabilizing drug that interferes with spindle assembly, elevated levels of mitotic cells were observed 5 h later in both genotypes (Fig. 2D). This result is consistent with data from MEFs showing that *Mps1^{DK}*-expressing cells arrest in the presence of spindle damage.

To assay tumor formation in a sensitized environment, we generated *Mps1^{f/f}* *Lck-Cre⁺* animals heterozygous for a FLOX-p53 allele (25). Loss of p53 suppresses aneuploidy-associated apoptosis in multiple cell types and is oncogenic in thymocytes (26–28). *Mps1^{f/f}* *p53^{f/+}* *Lck-Cre⁺* mice rapidly developed T-cell acute lymphoblastic lymphomas (T-ALL); $\sim 50\%$ of animals had died of the disease by age 3.5 mo, and 100% had died by age 5 mo (Fig. 2C, dark green line). In contrast, heterozygosity at *Mps1* had little effect on the survival of *p53*-null mice: *Mps1^{f/+}* *p53^{f/f}*




Fig. 2. *Mps1* truncation provokes aneuploidy in vivo and decreases T-ALL latency in a *p53*-compromised background. (A) Distribution of DNA content in control and *Mps1^{DK}* T cells. At least 10,000 T cells were counted. (B) Coefficient of variation values for the DNA content within G1 peaks in cell-cycle profiles of *Mps1^{DK/DK}* and *Cre⁻* T cells. Error bars show the SEM of more than five biological replicates for experimental animals or more than two replicates for control animals. (C) Kaplan–Meier curves showing overall survival of indicated genotypes. (D) Average mitotic index (% pH3) of thymocytes isolated from paclitaxel- or control-injected mice 4–6 h posttreatment. Error bars show SEM of more than five biological replicates in experimental animals or more than two replicates in control animals. (E) qPCRs showing complete loss of expression of *p53* (*p53* probes A and B) in lymphomas of indicated genotypes. Error bars show SEM for at least three tumors per genotype. (F) aCGH data showing the loss of the kinetochore-binding sequence in *Mps1* in tumors with the indicated genotypes. Each rectangle represents a single aCGH probe value. Three probes values are shown: one probe recognizing the kinetochore-binding domain (Center) and two probes flanking the 5' (Left) and 3' (Right) sides of the deleted region. Log₂ ratios less than -5 indicate complete loss of the indicated probe. Numbers on the left refer to tumor identification numbers (TID) (Dataset S1). (G) qPCRs showing full conversion of *Mps1^{WT}* to *Mps1^{DK}* in tumors with the indicated genotypes. Primer set A recognizes the sequence deleted in *Mps1^{DK}*, and set B detects a fragment in the kinase domain. (H) *Mps1* protein levels in *p53^{fl/fl}* (TIDs 38 and 63 and full-length *Mps1*) and *Mps1^{DK} p53^{fl/fl}* tumors (TIDs 18 and 19) showing the conversion of full-length to truncated *Mps1* in the latter genotype. The asterisk indicates a background band recognized in all lysates and runs just below *Mps1^{DK}* that is detected only in TIDs 18 and 19.

Lck-Cre⁺ animals had survival curves indistinguishable from those of *p53^{fl/fl} Lck-Cre⁺* mice (Fig. S2B). In addition, *Mps1* wild-type *p53^{fl/fl} Lck-Cre⁺* mice rarely developed disease, and tumor-free survival was indistinguishable from that of *Lck-Cre⁺* control animals (Fig. 2C, compare dark blue and black lines) (29). Thus, the *Mps1^{DK}* mutation is strongly oncogenic in T cells on a *p53^{fl/fl}* background.

Mps1^{DK} promoted loss of heterozygosity (LOH) at the *p53* locus: the PCR product corresponding to *p53^A* was substantially more abundant than the product corresponding to wild-type *p53* in DNA from *Mps1^{fl/fl} p53^{fl/fl} Lck-Cre⁺* tumors (Fig. S2C, compare tumors 9–17 with 18–21). Quantitative PCR (qPCR) data were consistent with this finding: *p53* mRNA was virtually undetectable in tumors recovered from *Mps1^{fl/fl} p53^{fl/fl}* animals (Fig. 2E). To characterize the LOH event, we extracted probe values from array-based comparative genomic hybridization (aCGH) for 17

tumors arising in *Mps1^{fl/fl} p53^{fl/fl}* animals (Fig. S2D). In all but two animals (tumors 12 and 39), hybridization to *p53* probes was low, similar to that of *p53*-null tumors from *Mps1^{fl/fl} p53^{fl/fl}* animals (compare Fig. S2D and E). Hybridization to neighboring probes was unaffected, suggesting that the wild-type copy of *p53* had been replaced by *p53^A* through either CIN or mitotic recombination. We conclude that *Mps1* truncation facilitates *p53* LOH, a highly oncogenic event in thymocytes (29–31).

The protumorigenic effects of *Mps1* truncation do not appear to involve *p53* LOH alone. Tumor induction was significantly faster in *Mps1^{fl/fl} p53^{fl/fl} Lck-Cre⁺* (and *Mps1^{fl/fl} p53^{fl/fl} Lck-Cre⁺*) mice than in *p53^{fl/fl} Lck-Cre⁺* mice, with death of 50% of the former animals by age 3.5 mo as opposed to 5 mo for the latter ($P < 0.0001$) (Fig. 2C). Analysis of mRNA and genomic DNA confirmed efficient Cre-mediated deletion of *p53* in tumors having either genotype (Fig. 2E and Fig. S2C–E). Moreover, accelerated tumorigenesis in *Mps1^{fl/fl} p53^{fl/fl}* double-mutant animals relative to *p53^{fl/fl}* animals was confirmed with a second Cre driver, mouse mammary tumor virus (*MMTV*)-*Cre*, which is transcribed in both T cells and the mammary gland (Fig. S2F) (32). However, no mammary tumors were observed in these animals, presumably because T-ALL developed before breast cancers could emerge.

To show that tumors comprised cells in which the *Mps1^{fl}* loci had been excised and thus that lymphomagenesis was not driven by *p53* loss alone (a concern because *p53* is such a strong tumor suppressor in T cells), we measured the efficiency of Cre-mediated recombination at the *Mps1* genomic locus. We assayed *Mps1* mRNA levels using PCR and aCGH, and we performed Western blotting. In tumors isolated from *Mps1^{fl/fl} p53^{fl/fl}* and *Mps1^{fl/fl} p53^{fl/fl}* mice, bands corresponding to *Mps1^{DK}* were the predominant amplified products (Fig. S2G and Dataset S1) in both *Lck-Cre⁺* and *MMTV-Cre⁺* backgrounds. In the aCGH data, we observed nearly complete loss of hybridization to sequences excised by Cre-mediated recombination of the *Mps1^{fl/fl}* locus (Fig. 2F). qPCR of tumor RNA also confirmed the loss of *Mps1* expression: Probes selective for the nonmutated 3' domain (*Mps1* probe set B; Fig. 2G and Fig. S2H) yielded a strong qPCR product, whereas probes corresponding the 5' region of *Mps1* deleted in *Mps1^{DK}* (*Mps1* probe set A) were ~ 20 -fold less abundant in tumors than in wild-type thymus DNA. Moreover, RT-PCR followed by Sanger sequencing confirmed the presence of correctly recombined *Mps1^{DK}* transcript (in tumors 13 and 23) and full-length *Mps1* in *p53^{fl/fl}* tumors (tumors 36 and 63) (Fig. S2I and Dataset S2). qPCR also showed that *Mps1^{DK}* is overexpressed in tumors by approximately fourfold relative to wild-type *Mps1* in parental cells, presumably because the elevated expression of the hypomorphic allele confers a selective advantage on cells. Finally, by Western blotting we could detect a protein band corresponding to the expected length of the *Mps1^{DK}* protein in *Mps1^{fl/fl} p53^{fl/fl} Lck-Cre⁺* tumor samples (tumors 18 and 19; Fig. 2H). We conclude that the *Mps1^{DK}* allele was maintained in the great majority of T cells throughout the development of a tumor, and thus the acceleration in tumorigenesis observed in double-mutant animals reflects ongoing synergy between *Mps1* and *p53* mutations.

***Mps1^{DK}*-Driven Tumors Exhibit Recurring Chromosomal Abnormalities.**

To determine the extent of aneuploidy in *Mps1^{DK}* T-ALL, we used aCGH to quantify chromosome copy number across the genome and interphase FISH to quantify chromosome number in single cells. aCGH revealed frequent loss and gain events for multiple chromosomes (four representative plots are shown in Fig. 3A, and normalized aCGH data are summarized in Dataset S3). As a simple measure of CIN, we summed the total number of chromosome gain and loss events in each tumor to create an “aneuploidy index.” The aneuploidy index ranged from 3 to 19 in 30 tumor samples examined and was significantly higher in




Fig. 3. Mps1 truncation leads to CIN and clonally stable karyotypes in tumors. (A) Representative aCGH profiles for four tumors showing whole-chromosome instability. (B) Aneuploidy index (total number of whole chromosomes gained and lost as assessed by aCGH) for tumors with the indicated genotypes. (C) Single-linkage hierarchical cluster analysis for individual tumors (top to bottom) and CGH probes (left to right). Clustering was separated visually into 20 clear groups. (D) Representative interphase FISH images of control (Top), Mps1^{DK} T cells (Middle), and Mps1^{DK} T-ALL cells (Bottom) showing copy numbers for Chr15 (green) and Chr17 (red).

tumors arising in Mps1^{fl/fl} p53^{fl/fl} or Mps1^{fl/fl} p53^{fl/+} animals (average indices of 8.2 and 7.6, respectively) than in p53^{fl/fl} animals (average index 2.4; $P = 0.047$ and $P = 0.028$, respectively) (Fig. 3B). Similarly, unsupervised single-linkage hierarchical clustering of cumulative aCGH data showed that tumors from Mps1^{fl/fl} mice heterozygous (Mps1^{fl/fl} p53^{fl/fl}) or homozygous (Mps1^{fl/fl} p53^{fl/+}) for p53 deletion clustered together and had more chromosomal abnormalities (Fig. 3C; green numbers) than tumors from p53^{fl/fl} animals that had less severe aneuploidy (Fig. 3C; blue numbers). Probes lying on the same chromosomes coclustered across all tumor samples, demonstrating that a significant fraction of the aneuploidy in these tumors involved gain and loss of whole chromosomes.

Amplification of Chr15 was particularly frequent in aCGH data, regardless of genotype, and is known to be common feature of mouse T-ALLs (7, 33, 34). In addition, amplification of Chr4 and Chr14 and to a lesser extent Chr9 was observed in many tumors, and Chr13 and Chr19 were commonly deleted, suggesting that those chromosomes carry genes important for transformation or aneuploid tumor progression. Interphase FISH confirmed aneuploidy in nontransformed Mps1-mutant thymocytes and heterogeneity in chromosome number within a single tumor. For example, Chr15 and Chr17 were aneuploid in a greater number of Mps1^{fl/fl} Lck-Cre⁺ thymocytes than in wild-type thymocytes (an average of 5% vs. 11% of cells for Chr15 and 6% vs. 12% of cells for Chr17) (Fig. S2J). In Mps1^{fl/fl} p53^{fl/+} Lck-Cre⁺ T-ALL tumors we observed Chr15 trisomy in up to 80% cells, but the

fraction of cells involved differed among animals (Fig. 3D and Fig. S2J).

To identify common focal loss and gain events, we performed genome-wide cumulative segmental gain or loss analysis (SGOL) comparing Mps1^{DK}-driven and p53^{fl/fl} Lck-Cre⁺ tumors. For both tumor classes, SGOL revealed strong deletion peaks on Chr6 and Chr14, consistent with a unique pattern of recombined T-cell receptor α/β loci. These results strongly suggest that tumors arose from a single parental T cell (Fig. S3A and B). We can reconcile the SGOL and FISH data by hypothesizing that T-ALLs are clonal early in their development [at the time of T-cell receptor (TCR) rearrangement] but that ongoing CIN results in subsequent chromosome loss and gain. Selection is expected to maintain some aneuploidies, e.g., Chr15 amplification, whereas other chromosomes (e.g., Chr17) might be subjected to ongoing loss and gain.

Recent studies on budding yeast and MEFs carrying supernumerary chromosomes have shown proportional increases in gene copy number and transcription (6, 8). To determine if these increases are present in tumors driven by Mps1 truncation, we used Illumina expression arrays to analyze the transcriptomes of 22 tumor samples that previously had been studied by aCGH as well as thymus DNA isolated from 6-wk-old wild-type mice. A strong correlation between mRNA and gene copy number was observed when aCGH values and expression levels were sorted by chromosomal position (Fig. S3C and D). When we calculated the average expression changes per individual chromosome for each tumor (using healthy thymic samples as a control) and then compared the value with the aCGH intensity (Fig. 4A and B and Dataset S4), the correlation between expression and copy number was $R^2 = 0.44$ –0.76 for the most commonly aneuploid chromosomes (Chr4, Chr14, and Chr15). (Fig. 4C and Fig. S4 show correlation for all chromosomes.) We conclude that in tumors, as in cultured cells, chromosomal imbalances on average are translated into increases and decreases in transcription, and thus there is little or no dosage compensation.

Mps1^{DK} Tumors Show Evidence of Aneuploidy-Induced Stress. To identify genes significantly over- and underexpressed in T-ALLs, we sorted genes by their cumulative expression changes across all samples (annotated in Fig. S5A and Dataset S4). For Chr4, Chr14, and Chr15, the majority of genes had a positive cumulative score; the reverse was true for Chr19, reflecting the correlation between changes in transcription and gene copy number. Among the outliers we found several that exhibited an inverse correlation between copy number and expression including the keratins *Krt*, 5, 7, 8, and 18, *Eps1l*, and *Chdrl*. These genes are expressed in the thymic cortex and not in tumor cells, and their lower expression in mutant animals likely reflects T-ALL-mediated depletion of cortical tissue. A second set of outlier genes was significantly overexpressed relative to other genes on the same chromosome. This set includes genes involved in cell metabolism (*Srm*, *Gln3*, *Cox6a*, *Drospha*, and *Adk*), cellular stress (*Serp2* and *Hsf1*), cell cycle (*Recql4*, *Cdkn2a*, *Skp2*, and *Tnc*), and epigenetic regulation (*Prmt5* and *Cbx5*). Surprisingly, *Myc*, a known oncogene in T-ALL (7), was not among the strongest positive outliers on Chr15. In future work it should be possible to use Mps1^{DK}-driven aneuploidy to identify new oncogenes or tumor suppressors involved in T-ALL as well as genes involved in cell survival in the presence of CIN.

To begin to identify biological pathways altered by aneuploidy, we compared probes that were up- or down-regulated at least 1.5-fold in >15% of tumors analyzed (4 of 22); we identified ~3,300 genes by this analysis. We then used WebGestalt (35) to find Gene Ontology (GO) categories that were significantly enriched (using a Bonferroni corrected P value < 0.05). The most commonly deregulated pathways were TCR signaling, mRNA processing, cell cycle, and pathways involved in cellular




Fig. 4. Gene copy number results in proportional transcription changes in aneuploid tumors. (A and B) Average aCGH (A) or RNA expression values (B) were calculated per chromosome for each tumor and plotted for each tumor group. Each individual symbol represents the average value of that chromosome in one tumor; black crosses show the mean and SEM across all tumors per chromosome. (C) Linear regression plots showing the correlation strength (coefficient of correlation, R^2) between copy number changes (aCGH) and expression changes (expression arrays) for frequently gained Chr4, Chr14, and Chr15.

metabolism (Fig. S3E). When we performed hierarchical clustering of deregulated genes (Fig. 5), dividing clusters into five groups based on whether genes were strongly or weakly up- or down-regulated, T-cell differentiation and signaling factors were down-regulated; this result is consistent with histological data showing that tumors are poorly differentiated. In contrast, pathways involved in cellular metabolisms (GO terms for “metabolic pathways,” “RNA metabolic pathways,” “spliceosome,” “translation factors,” “nucleotide synthesis,” and others) were up-regulated. Misregulation of these processes previously has been associated with aneuploid stress in cultured mammalian cells and budding yeast (6, 8, 36, 37). We conclude that dysregulation of metabolic pathways is a common feature of CIN in multiple organisms and cell types, including rapidly growing tumors.

Discussion

In this article we report the development and analysis of mice in which CIN and consequent aneuploidy are induced in a rapidly proliferating but nonessential adult tissue by conditionally truncating the SAC kinase *Mps1*. We show that the *Mps1* truncation, which deletes a kinetochore-targeting domain but leaves kinase activity and other functions intact, can provoke but not sustain a checkpoint arrest in the presence of spindle poison; it also

causes chromosome misalignment and generates lagging chromosomes, consistent with the dual role of SAC proteins in promoting and sensing kinetochore attachment. When mutated in murine T cells, *Mps1* truncation causes aneuploidy, but this aneuploidy is insufficient for efficient oncogenic transformation. However, in a predisposed *p53* heterozygous-deletion background, *Mps1* truncation results in rapidly growing T-ALL. We observe frequent *p53* LOH in *Mps1^{fl} p53^{fl} Lck-Cre⁺* animals, consistent with the known role of *p53* as a potent tumor suppressor in T cells. However, *p53* LOH cannot be the only oncogenic event in T-ALLs, because tumor latency is significantly shorter in *Mps1^{fl} p53^{fl} Lck-Cre⁺* animals than in *p53^{fl} Lck-Cre⁺* animals. aCGH also reveals higher levels of aneuploidy in compound-mutant animals than in single mutants. Taken together, these data suggest that *Mps1* mutation causes *p53* LOH and that the combined *Mps1-p53* mutant genotype results in more efficient gain and loss of cancer genes than *p53* mutation alone.

We interpret aCGH and interphase FISH data to show that T-ALLs are initially clonal (based on TCR rearrangement) but that ongoing CIN results in tumors with recurrent aneuploidies in Chr4, Chr14, Chr15, and Chr19 as well as sporadic changes in other chromosomes. The net result is changes in the expression of oncogenes and tumor suppressors driving T-ALL as well as changes in as yet unidentified pathways involved in tolerizing cells to aneuploidy. A significant body of literature has emerged over the past few years examining the consequences of aneuploidy for the physiology of yeast and cultured murine fibroblasts. These studies have revealed recurrent up-regulation of pathways involved in mRNA processing and other metabolic processes (6, 8, 37). Our data show that T-ALLs generated by *Mps1* truncation and *p53* loss also exhibit transcriptional signatures similar to those of aneuploid MEFs (6) and untransformed tissues (36). Thus, T-ALLs cells can grow rapidly in the face of frequent chromosome loss and gain, but CIN nonetheless imposes a burden on tumor cells similar to that observed in MEFs and budding yeast cells. This finding is potentially significant, because proteotoxic stress and metabolic dysregulation have become important targets for cancer therapy and may represent a means to kill highly aneuploid cancers selectively.

Materials and Methods

Analysis of Mice. Mice used in this study had a mixed C57BL/6 and 129/Sv D3 genetic background. *Mps1* conditional mice harboring a deletion of residues 47–154 were generated as described in *SI Materials and Methods*. *p53* conditional-knockout mice were obtained from Anton Berns (Department of




Fig. 5. *Mps1^{DK}*-driven CIN activates genes regulating various aspects of cellular metabolism. Single-linkage hierarchical clustering of transcriptome data shows the most significant deregulated pathways per group. Groups I–V were grouped by visual inspection. Full gene lists and enrichment analyses are in [Dataset S4](#).

Genetics, The Netherlands Cancer Institute, Amsterdam, The Netherlands) (25), *Lck-Cre* transgenic mice from Taconic (38), and *MMTV-Cre* mice (39) from the MIT mouse repository. Mice were intercrossed to obtain the described strains and genotyped as described previously (25, 39). (Genotyping PCR primers are given in [Dataset S5](#).) For survival studies, mice were monitored for tumor development weekly starting at 2.5 mo of age by looking for difficulty in breathing (a consequence of thymic hypertrophy). Tissues were fixed in 10% formalin and then paraffin-embedded for histology. Animal protocols were approved by the MIT, Harvard Medical School, and University of Groningen Medical Center Committees on Animal Care and by the U.K. Home Office.

MEF Isolation, Transduction, Flow Cytometry, and Time-Lapse Analysis. MEFs were isolated as described previously (40) at E13.5 from *Mps1^{fl/fl}* embryos and were cultured under low-oxygen (3%) conditions. Retroviral particles (pRetrox system; Clontech) were produced in Lipofectamine 2000-transfected (Life Technologies) 293T cells. MEFs were first transduced with pRetrox-rtTA virus and next with pRetrox-GFP-T2A-Cre virus, allowing us to assess Cre expression without linking Cre to GFP directly (41), or with pRetrox GFP-*Mps1^{WT}* or GFP-*Mps1^{DK}* virus (constructs are described in detail in [SI Materials and Methods](#)). For time-lapse imaging, cells subsequently were transduced with pRetrox-H2B-Cherry or pRetrox-H2B-GFP to visualize the DNA and were treated with 250 ng/mL nocodazole (Sigma) where indicated. For flow cytometry, transduced cells were treated with 1 μ g/mL Dox (Sigma) for 48–72 h to induce the retroviral inserts, then were treated with 250 ng/mL nocodazole for 6 h, and were fixed in 70% ethanol. Cells then were stained with phycoerythrin-labeled pHistoneH3 antibody (Cell Signaling) and FxCycle Brilliant blue (Life Technologies) and analyzed on an LSRII analyzer (BD Biosciences). Data were analyzed using FlowJo software. For time-lapse analysis, cells were seeded on LabTek imaging chambers (Thermo Fisher), induced with 1 μ g/mL Dox for 48–72 h, and imaged for up to 36 h on a DeltaVision Elite imaging station (Applied Precision, GE Healthcare) in a low-oxygen

imaging chamber (Oko Laboratories). Movies were deconvolved and analyzed using SoftWorx suite (GE Healthcare).

DNA/RNA/Protein Isolation, Array, and Blotting Experiments. Genomic DNA from tumor samples and control liver was isolated using genomic DNA tissue kits (Qiagen). Genotyping primers are listed in [Dataset S5](#). Protein was isolated using a total protein extraction kit (Millipore). For protein detection, proteins were blotted using standard Western blotting protocols. The antibodies used were *Mps1* (TTK-C19, Santa Cruz) and HRP-conjugated goat anti-rabbit (Cell Signaling). For aCGH experiments, labeled DNA ([SI Materials and Methods](#)) was hybridized to 244K mouse genome CGH arrays (Agilent) according to the manufacturer's protocol and was analyzed as described in [SI Materials and Methods](#). RNA was isolated from tumor samples and from the thymuses from 6-wk-old control mice using the RNeasy kit (Qiagen). Labeled RNA ([SI Materials and Methods](#)) was hybridized to Illumina v6.2 BeadChip arrays and was scanned and analyzed as described in [SI Materials and Methods](#). qPCR primers are listed in [Dataset S5](#). All array data have been deposited in the National Center for Biotechnology Information Gene Expression Omnibus database under accession no. GSE57334.

ACKNOWLEDGMENTS. We thank members of the P.K.S. laboratory, S. W. M. Bruggeman, L. Albacker, and L. Kleiman for critically reading the manuscript and fruitful discussions; B. Bakker for assistance with cloning; Roderick Bronson for help with pathology; and A. Burds for sharing *Lck-Cre* and *MMTV-Cre* mice. This work was supported by Dutch Cancer Society Grant RUG 2012-5549; by grants from Stichting Kinder Oncologie Groningen and European Molecular Biology Organization (to F.F.); by National Institutes of Health (NIH) Grants CA084179 and CA139980 (to P.K.S.); by NIH Grant P30-CA14051 to the MIT mouse transgenic facility; and by the Wellcome Trust (F.F. and A.B.).

- Duijff PH, Schultz N, Benezra R (2013) Cancer cells preferentially lose small chromosomes. *Int J Cancer* 132(10):2316–2326.
- Schwartzman JM, Sotillo R, Benezra R (2010) Mitotic chromosomal instability and cancer: Mouse modelling of the human disease. *Nat Rev Cancer* 10(2):102–115.
- Holland AJ, Cleveland DW (2009) Boveri revisited: Chromosomal instability, aneuploidy and tumorigenesis. *Nat Rev Mol Cell Biol* 10(7):478–487.
- Foijer F, Draviam VM, Sorger PK (2008) Studying chromosome instability in the mouse. *Biochim Biophys Acta* 1786(1):73–82.
- Baker DJ, Jin F, Jegannathan KB, van Deursen JM (2009) Whole chromosome instability caused by Bub1 insufficiency drives tumorigenesis through tumor suppressor gene loss of heterozygosity. *Cancer Cell* 16(6):475–486.
- Williams BR, et al. (2008) Aneuploidy affects proliferation and spontaneous immortalization in mammalian cells. *Science* 322(5902):703–709.
- Jones L, et al. (2010) Gain of MYC underlies recurrent trisomy of the MYC chromosome in acute promyelocytic leukemia. *J Exp Med* 207(12):2581–2594.
- Torres EM, et al. (2007) Effects of aneuploidy on cellular physiology and cell division in haploid yeast. *Science* 317(5840):916–924.
- Kops GJ, Foltz DR, Cleveland DW (2004) Lethality to human cancer cells through massive chromosome loss by inhibition of the mitotic checkpoint. *Proc Natl Acad Sci USA* 101(23):8699–8704.
- Mao R, Zielke CL, Zielke HR, Pevsner J (2003) Global up-regulation of chromosome 21 gene expression in the developing Down syndrome brain. *Genomics* 81(5):457–467.
- Baker DJ, et al. (2004) BubR1 insufficiency causes early onset of aging-associated phenotypes and infertility in mice. *Nat Genet* 36(7):744–749.
- Baker DJ, et al. (2006) Early aging-associated phenotypes in Bub3/Rae1 haploinsufficient mice. *J Cell Biol* 172(4):529–540.
- Baker DJ, et al. (2013) Increased expression of BubR1 protects against aneuploidy and cancer and extends healthy lifespan. *Nat Cell Biol* 15(1):96–102.
- Jallepalli PV, Lengauer C (2001) Chromosome segregation and cancer: Cutting through the mystery. *Nat Rev Cancer* 1(2):109–117.
- Taylor SS, Scott MI, Holland AJ (2004) The spindle checkpoint: A quality control mechanism which ensures accurate chromosome segregation. *Chromosome Res* 12(6):599–616.
- Rieder CL, Cole RW, Khodjakov A, Sluder G (1995) The checkpoint delaying anaphase in response to chromosome monoorientation is mediated by an inhibitory signal produced by unattached kinetochores. *J Cell Biol* 130(4):941–948.
- Musacchio A, Salmon ED (2007) The spindle-assembly checkpoint in space and time. *Nat Rev Mol Cell Biol* 8(5):379–393.
- Weaver BA, Silk AD, Montagna C, Verdier-Pinard P, Cleveland DW (2007) Aneuploidy acts both oncogenically and as a tumor suppressor. *Cancer Cell* 11(1):25–36.
- Jonkers J, Berns A (2002) Conditional mouse models of sporadic cancer. *Nat Rev Cancer* 2(4):251–265.
- Janssen A, Kops GJ, Medema RH (2009) Elevating the frequency of chromosome mis-segregation as a strategy to kill tumor cells. *Proc Natl Acad Sci USA* 106(45):19108–19113.
- Hached K, et al. (2011) *Mps1* at kinetochores is essential for female mouse meiosis I. *Development* 138(11):2261–2271.
- Nijenhuis W, et al. (2013) A TPR domain-containing N-terminal module of MP51 is required for its kinetochore localization by Aurora B. *J Cell Biol* 201(2):217–231.
- Rudner AD, Murray AW (1996) The spindle assembly checkpoint. *Curr Opin Cell Biol* 8(6):773–780.
- Hennet T, Hagen FK, Tabak LA, Marth JD (1995) T-cell-specific deletion of a polypeptide N-acetylgalactosaminyl-transferase gene by site-directed recombination. *Proc Natl Acad Sci USA* 92(26):12070–12074.
- Jonkers J, et al. (2001) Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. *Nat Genet* 29(4):418–425.
- Burds AA, Lutum AS, Sorger PK (2005) Generating chromosome instability through the simultaneous deletion of Mad2 and p53. *Proc Natl Acad Sci USA* 102(32):11296–11301.
- Thompson SL, Compton DA (2010) Proliferation of aneuploid human cells is limited by a p53-dependent mechanism. *J Cell Biol* 188(3):369–381.
- Fujiwara T, et al. (2005) Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells. *Nature* 437(7061):1043–1047.
- Donehower LA, et al. (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. *Nature* 356(6366):215–221.
- Purdie CA, et al. (1994) Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53 gene. *Oncogene* 9(2):603–609.
- Jacks T, et al. (1994) Tumor spectrum analysis in p53-mutant mice. *Curr Biol* 4(1):1–7.
- Wagner KU, et al. (2001) Spatial and temporal expression of the Cre gene under the control of the MMTV-LTR in different lines of transgenic mice. *Transgenic Res* 10(6):545–553.
- Zha S, et al. (2010) ATM-deficient thymic lymphoma is associated with aberrant tcrd rearrangement and gene amplification. *J Exp Med* 207(7):1369–1380.
- Takabatake T, et al. (2008) Analysis of changes in DNA copy number in radiation-induced thymic lymphomas of susceptible C57BL/6, resistant C3H and hybrid F1 Mice. *Radiat Res* 169(4):426–436.
- Zhang B, Kirov S, Snoddy J (2005) WebGestalt: An integrated system for exploring gene sets in various biological contexts. *Nucleic Acids Res* 33(Web Server issue):W741–748.
- Foijer F, et al. (2013) Spindle checkpoint deficiency is tolerated by murine epidermal cells but not hair follicle stem cells. *Proc Natl Acad Sci USA* 110(8):2928–2933.
- Sheltzer JM, Torres EM, Dunham MJ, Amon A (2012) Transcriptional consequences of aneuploidy. *Proc Natl Acad Sci USA* 109(31):12644–12649.
- Lee PP, et al. (2001) A critical role for Dnm1 and DNA methylation in T cell development, function, and survival. *Immunity* 15(5):763–774.
- Wagner KU, et al. (1997) Cre-mediated gene deletion in the mammary gland. *Nucleic Acids Res* 25(21):4323–4330.
- Foijer F, Wolthuis RM, Doodeman V, Medema RH, te Riele H (2005) Mitogen requirement for cell cycle progression in the absence of pocket protein activity. *Cancer Cell* 8(6):455–466.
- Szymczak AL, et al. (2004) Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. *Nat Biotechnol* 22(5):589–594.